Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Translation Needed | Main | Excel and Exceed, Y'all »

May 5, 2011

When Lipitor Goes Generic

Email This Entry

Posted by Derek

So, when Lipitor goes generic later this year, it's Ranbaxy that's going to step in and make the big bucks for a few months, right? Well. . .there's room to wonder. Ranbaxy has had some severe regulatory problems, and other companies are trying to see if they can use those to their advantage. Fortune magazine has more:

You'd think that in this era of generic-drug dominance, making the transition to a nonbranded version of Pfizer's vaunted cholesterol-fighting statin would be smooth, or at least controlled. And indeed, that's precisely how it seemed -- until just a few months ago. Now the process appears to have unraveled, leaving serious questions about who will make the cheaper form of Lipitor, whether the price will really drop, and most disturbing of all, whether patients will be able to trust that the medication is safe. . .

Comments (14) + TrackBacks (0) | Category: Regulatory Affairs


COMMENTS

1. Still Scared of Dinosaurs on May 5, 2011 11:56 AM writes...

And yet the age of biosimilars is upon us. There are multiple cases of a company failing to recreate its own drug and yet somehow cost-conscious generics companies are going to pull it off?

"It could happen."
- Judy Tenuta

Permalink to Comment

2. patentgeek on May 5, 2011 12:11 PM writes...

One of those seeking to use Ranbaxy's problems to their advantage is Mylan. Their suit to force FDA to determine whether Ranbaxy had forfeited the 180-day exclusivity period was dismissed in DC District Court earlier this week (lack of subject matter jurisdiction). (Mylan Pharms. v. FDA and Ranbaxy Labs., No. 11-566-JEB (D.D.C. 2011)
More at http://www.orangebookblog.com/

Permalink to Comment

3. DrSnowboard on May 5, 2011 12:21 PM writes...

But if we were misguided to follow this advice http://www.bbc.co.uk/news/health-13284032, show me the money.

Risk of disease correlates with increased age, who knew?

Permalink to Comment

4. anon the II on May 5, 2011 12:32 PM writes...

My sense is that this is all Pfizer PHUD, which they learned from IBM and Microsoft.

Phear, Uncertainty and Doubt.

Permalink to Comment

5. Anonymous on May 5, 2011 12:35 PM writes...

2: You have comma included in the link so it does not work.


http://www.bbc.co.uk/news/health-13284032

Permalink to Comment

6. ex-Pfizerite on May 5, 2011 12:40 PM writes...

You need to remember that Pfizer has a major generic group called Greenstone, so will Pfizer launch its own generic before Ranbaxy and stuff the channels?

Permalink to Comment

7. lynn on May 5, 2011 12:51 PM writes...

I think Merck should manufacture and sell generic lipitor. Or combine it with zetia. :-)

Permalink to Comment

8. Nate on May 5, 2011 3:51 PM writes...

#6, I didn't think authorized generics (as greenstones) would be are allowed to play with the 180 day rule. But I could be wrong

Permalink to Comment

9. Matthew Herper on May 5, 2011 5:12 PM writes...

#6, I think Watson is making the authorized generic in this case. If Ranbaxy does not launch in time, Watson will still launch in November, I believe.

Permalink to Comment

10. ex-Pfizerite on May 5, 2011 7:12 PM writes...

With regard to 8 and 9 an authorized generic is not a generic because it does not have an ANDA but is sold as part of the branded drugs authorization. In theory Pfizer could sell an authorized generic tomorrow and Ranbaxy could do nothing about id absent an agreement in the settlement.

Permalink to Comment

11. Virgil on May 6, 2011 8:04 AM writes...

Hmmm... I wonder how much Pfizer paid Fortune mag for that little piece, casing doubt over the safety of generics?

Permalink to Comment

12. Kaleberg on May 6, 2011 11:16 PM writes...

Selling a generic version of one's own drug makes sense. It's like the fashion business where designers sell a full range of knock offs of their designs for the mid-market and even for the outlet store low end market. Why let someone else capture the sales?

Permalink to Comment

13. Nice on May 7, 2011 9:49 AM writes...

Hmmm... I wonder how much Pfizer paid Ranbaxy to have problems and delay the generic launch so that they could continue only selling branded lipitor. Every month adds another billion dollars or so.

Permalink to Comment

14. oldtimer on May 10, 2011 4:38 PM writes...

Don't forget Lipitor is not a Pfizer drug, they "liked it so much they bought the company"

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All